Ikarian Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.92M Sell
598,281
-160,373
-21% -$3.57M 0.72% 37
2025
Q4
$19M Buy
+758,654
New +$13.5M 1.48% 15
2025
Q2
Sell
-191,994
Closed -$722K 174
2025
Q1
$722K Buy
191,994
+100,000
+109% +$503K 0.09% 103
2024
Q4
$536K Sell
91,994
-6
-0% -$60 0.07% 130
2024
Q3
$1.1M Buy
+92,000
New +$1.18M 0.15% 93

Other funds holding OLMA

Ikarian Capital's OLMA Position: Q1 2026 in Review

Ikarian Capital reduced its Olema Pharmaceuticals (OLMA) stake by 21% in Q1 2026, selling an estimated $3.57M and leaving 598,281 shares worth $8.92M. The position accounts for 0.72% of the portfolio, ranked #37.

Ikarian Capital first reported a position in OLMA in Q3 2024 and has held it in 5 quarters since. The position peaked at $19M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Ikarian Capital held 598,281 shares of Olema Pharmaceuticals worth $8.92M as of Q1 2026.
  • Ikarian Capital sold 160,373 Olema Pharmaceuticals shares in Q1 2026, an estimated $3.57M.
  • Olema Pharmaceuticals made up 0.72% of Ikarian Capital's portfolio in Q1 2026, its #37 holding.
  • Ikarian Capital first reported a position in Olema Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Ikarian Capital's Olema Pharmaceuticals position peaked at $19M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.